DBV Technologies Provides Organizational Update

DBV Technologies Provides Organizational Update

BAGNEUX, France, January 8, 2015 - DBV Technologies, (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage

specialty biopharmaceutical company, today provided an organizational update, which included appointing David Schilansky as Chief Operating Officer ( Directeur G n ral D l gu ), Bertrand Dupont as Senior

Executive Vice President, Technology, Charles Ruban as Senior Executive Vice President, Clinical Development & North American Operations and Laurent Martin as Senior Executive Vice President, Product Strategy & Regulatory Affairs.

This new corporate organization reflects DBV s focus to become the leader in discovering, developing and commercializing food allergy treatments, while leveraging its Viaskin platform to develop innovative immunotherapy products.

Pierre-Henri Benhamou, M.D., Chairman and CEO of DBV Technologies said: 2014 was a very successful year for DBV.

Mr. Benhamou continued, On September 2014, we announced positive topline Phase IIb study results with Viaskin Peanut, validating the potential of our platform in food

allergy. We also successfully completed a $130 million Nasdaq IPO, allowing us to continue developing our product candidates independently, enrich our R&D programs and begin to build an operational infrastructure in the US. 2015 will be a

transformative year for DBV, and this new organizational structure enables us to focus on the last steps of Viaskin Peanut s development and its commercialization.

A new corporate organization, post proof-of concept of the Viaskin platform in food allergy

The company has announced the following senior management team changes in order to implement DBV s global growth strategy, advance business and

commercial efforts in North America and support and enhance product development:

2015 Financial Calendar

In 2015, DBV will announce the

company s financial and operating results as follows:

About DBV Technologies

DBV Technologies is developing Viaskin , an innovative new approach to the treatment of allergies

a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding

transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no

effective treatments. DBV Technologies has designed two products candidates: Viaskin Peanut and Viaskin Milk. The clinical

development program for Viaskin Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of

American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT).

Forward Looking Statements

This press release contains forward-looking statements, including the proposed 2015 financial calendar. These forward-looking statements are not promises or

guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development,

clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be

found in the Company s regulatory filings with the French Autorit des March s Financiers and the Registration Statement filed with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to

place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information,

future events or circumstances or otherwise.

DBV Technologies Contacts